PUBLISHED DATE : Mar 2022 | Pages : 207
Fill out your details & get your free sample
U.S. Gene Therapy Market Report Includes Size, Share, & Trends Analysis By
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2027
207 Pages
42 Tables
89 Charts
1 Regions
1 Countries
37 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (Revenue) | USD 16,013.28 Million (2027) |
| CAGR | 43.44% (2022-2027) |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments (Vector Type) | Retroviral and Others |
| Market Segments (Product) | Car T Therapy and Non-Car T Therapy |
| Market Segments (Indication) | Oncology and Others |
| Market Segments (Gene Transfer) | Ex-Vivo and In-Vivo |
| End User | Hospitals, Cancer Care Centers, and Academic & Research Centers |
The U.S. gene therapy market is projected to grow at a CAGR of 43% from 2022 to 2027 and is expected to reach USD 16.01 billion by 2027 from USD 1.8 billion in 2021. The gene therapy market in the U.S. is one of the fastest-growing segments of the regenerative medicine market. This growth can be attributable to the growing prevalence of various chronic diseases like cancer, cartilage-related problems, wounds, diabetic foot ulcers, genetic disorders, and other rare diseases across the United States. Further, the U.S. gene therapy market share is witnessing a steady growth due to increased funding availability from various public and private institutes. In addition, there is increased support from the U.S. regulatory bodies for product approvals and providing fast-track designations to the products, encouraging vendors to manufacture the products faster.
Gene therapy is a process in which the genes inside the body are altered to treat or stop the disease. Research and development activities in the U.S. gene therapy market are witnessing significant growth with support from both public and private entities. In 2020, the U.S. FDA saw a yearly doubling of new gene therapy applications. By 2025, the US is expected to approve 10–20 gene therapies yearly. In addition, the US government is creating awareness about gene therapies among the population and bringing various strategies to facilitate affordability and payments for these treatments. However, the demand for innovative medicines and therapies increased across the US. The investment in gene therapy has also increased drastically in recent years.
Gene transfer via retroviral vectors is central to the development of gene therapy. Recently, the broader field of gene transfer and gene therapy via retroviral vectors has been revived with the development of a new class of lentiviral-derived retroviral vectors. The retroviral US gene therapy market is expected to reach USD 8,861.75 million by 2027.
Advanced therapies such as CAR T-cell therapy are being introduced, prompting major countries to invest in the infrastructure and improve these therapies for patient populations. The U.S. gene therapy market is growing at a double-digit CAGR, which is expected to help the oncology segment as many cell and gene therapies are commercially available. Most of the recently launched drugs for cancer are fetching healthy revenues for manufacturers as they are more expensive than most cell and gene therapies.
With the significant increase in the development of in-vivo gene therapy in recent years, the biotechnology and pharmaceutical industries have invested heavily in commercializing these potentially curative therapies to treat various diseases. This is an exciting time for gene therapy, with AAV playing a leading role.
Gilead Sciences, Novartis, F. Hoffmann-La Roche, Amgen, bluebird bio, and Bristol Myers Squibb are the leading players with significant U.S. gene therapy market share. Many regional and local businesses threaten key players with innovative, cost-effective products and technologies. This shows that the market offers tremendous growth opportunities for existing and emerging players. Major players focus on licensing, strategic acquisitions, and collaboration agreements with emerging players to enter the gene therapy market and quickly access commercially launched products. The gene therapy market in the U.S. is highly consolidated, with Novartis and Gilead Sciences accounting for significant shares. Amgen and Spark Therapeutics are other vendors with notable shares in the U.S. gene therapy market.
Frequently Asked Questions
What is the expected U.S. Gene Therapy Market size by 2027?
The U.S. gene therapy market is expected to cross USD 16.0133 billion by 2027. This growth can be attributable to the growing prevalence of various chronic diseases like cancer, cartilage-related problems, wounds, diabetic foot ulcers, genetic disorders, and other rare diseases across the United States.
What are the latest trends in the U.S. gene therapy market?
Product launches & regulatory approvals and, regulatory support & special designations for gene therapies are the latest trends in the market.
Who are the key market players in the U.S. gene therapy market?
Key players include Amgen, bluebird bio, Bristol Myers Squibb, Gilead Sciences, Novartis, and F. Hoffmann-La Roche.
Which vector segments hold the major U.S. gene therapy market share?
Retroviral holds the largest share in the U.S. gene therapy market. Gene transfer via retroviral vectors is central to the development of gene therapy. Retroviral vectors are the most used type of gene delivery vectors for clinical gene therapy in the U.S. The significant advantages of retroviral vectors are the ability to stably integrate into the target cell genome and ease of manipulation to insert the therapeutic gene.
What initiatives are vendors taking in the gene therapy market in the U.S.?
High emphasis on R&D and augmented investment are some of the initiatives taken by vendors in the U.S. gene therapy market. Investing in R&D activities to develop novel therapies is key for the long-term sustainability of companies operating in the U.S. gene therapy market. Therefore, many players, including key and emerging companies and smaller vendors, are investing in many R&D activities.
U.S. gene therapy market size was valued at USD 1,838.49 million in 2021 and is expected to reach USD 16,013.28 million by 2027, growing at a CAGR of 43.44% during 2022-2027
The following factors are likely to contribute to the growth of the U.S. gene therapy market –
Base Year: 2021
Forecast Year: 2022-2027
The study considers a detailed scenario of the present U.S. gene therapy market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Key Vendors
Other Prominent Vendors
Market Segmentation by Vector Type
Market Segmentation by Product Type
Market Segmentation by Indication
Market Segmentation by Gene Transfer
Market Segmentation by End User
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY VECTOR
4.3.2 MARKET SEGMENTATION BY PRODUCT
4.3.3 MARKET SEGMENTATION BY INDICATION
4.3.4 MARKET SEGMENTATION BY GENE TRANSFER
4.3.5 MARKET SEGMENTATION BY END-USERS
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 BACKGROUND
7.2 GENE THERAPY: AN OVERVIEW
7.2.1 EVOLUTION OF GENE THERAPY
8 REIMBURSEMENT FOR GENE THERAPY IN US
8.1 OVERVIEW
9 REGULATORY SCENARIO FOR GENE THERAPY PRODUCTS
9.1 OVERVIEW
9.2 CLINICAL TRIAL PROCESS FOR GENE THERAPY
10 COMMERCIAL GENE THERAPY PRODUCTS IN US
10.1 OVERVIEW
10.1.1 ABECMA (IDECABTAGENE VICLEUCEL)
10.1.2 BREYANZI (LISOCABTAGENE MARALEUCEL)
10.1.3 TECARTUS (BREXUCABTAGENE AUTOLEUCEL)
10.1.4 ZOLGENSMA (ONASEMNOGENE ABEPARVOVEC)
10.1.5 LUXTURNA (VORETIGENE NEPARVOVEC)
10.1.6 YESCARTA (AXICABTAGENE CILOLEUCEL)
10.1.7 KYMRIAH (TISAGENLECLEUCEL-T)
10.1.8 IMLYGIC (TALIMOGENE LAHERPAREPVEC)
11 GENE THERAPY PRODUCTS IN PIPELINE
11.1 OVERVIEW
12 MARKET OPPORTUNITIES & TRENDS
12.1 INCREASING MARKET ACCESS FOR GENE THERAPIES
12.2 INTRODUCTION OF UNIVERSAL CAR-T THERAPY
12.3 INCREASE IN STRATEGIC ACQUISITIONS
12.4 INCREASED FUNDING FOR R&D ACTIVITIES OF GENE THERAPIES
13 MARKET GROWTH ENABLERS
13.1 INCREASE IN CMOS TO MANUFACTURE GENE THERAPIES
13.2 INCREASING TARGET PATIENT POPULATION
13.3 PRODUCT LAUNCHES & REGULATORY APPROVALS
13.4 REGULATORY SUPPORT & SPECIAL DESIGNATIONS FOR GENE THERAPIES
14 MARKET RESTRAINTS
14.1 HIGH COST OF GENE THERAPY PRODUCTS
14.2 LIMITATIONS OF GENE THERAPY PRODUCTS
14.3 AVAILABILITY OF ALTERNATIVE THERAPEUTICS & WITHDRAWAL OF PRODUCTS
15 MARKET LANDSCAPE
15.1 MARKET OVERVIEW
15.2 MARKET SIZE & FORECAST
15.2.1 INSIGHTS BY VECTOR TYPE
15.2.2 INSIGHTS BY PRODUCT TYPE
15.2.3 INSIGHTS BY INDICATION TYPE
15.2.4 INSIGHTS BY GENE TRANSFER TYPE
15.2.5 INSIGHTS BY END-USERS
15.3 FIVE FORCES ANALYSIS
15.3.1 THREAT OF NEW ENTRANTS
15.3.2 BARGAINING POWER OF SUPPLIERS
15.3.3 BARGAINING POWER OF BUYERS
15.3.4 THREAT OF SUBSTITUTES
15.3.5 COMPETITIVE RIVALRY
16 VECTOR TYPE
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 RETROVIRAL
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.4 OTHER VECTORS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
17 PRODUCT TYPE
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 CAR-T THERAPY
17.3.1 MARKET OVERVIEW
17.3.2 MARKET SIZE & FORECAST
17.4 NON-CAR-T THERAPY
17.4.1 MARKET OVERVIEW
17.4.2 MARKET SIZE & FORECAST
18 INDICATION
18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 MARKET OVERVIEW
18.3 ONCOLOGY
18.3.1 MARKET OVERVIEW
18.3.2 MARKET SIZE & FORECAST
18.4 OTHERS
18.4.1 MARKET OVERVIEW
18.4.2 MARKET SIZE & FORECAST
19 GENE TRANSFER
19.1 MARKET SNAPSHOT & GROWTH ENGINE
19.2 MARKET OVERVIEW
19.3 EX-VIVO
19.3.1 MARKET OVERVIEW
19.3.2 MARKET SIZE & FORECAST
19.4 IN-VIVO
19.4.1 MARKET OVERVIEW
19.4.2 MARKET SIZE & FORECAST
20 END-USERS
20.1 MARKET SNAPSHOT & GROWTH ENGINE
20.2 MARKET OVERVIEW
20.3 HOSPITALS
20.3.1 MARKET OVERVIEW
20.3.2 MARKET SIZE & FORECAST
20.4 CANCER CARE CENTERS
20.4.1 MARKET OVERVIEW
20.4.2 MARKET SIZE & FORECAST
20.5 ACADEMIC & RESEARCH CENTERS
20.5.1 MARKET OVERVIEW
20.5.2 MARKET SIZE & FORECAST
21 COMPETITIVE LANDSCAPE
21.1 COMPETITION OVERVIEW
21.2 MARKET SHARE ANALYSIS
21.2.1 AMGEN
21.2.2 BLUEBIRD BIO
21.2.3 BRISTOL MYERS SQUIBB
21.2.4 GILEAD SCIENCES
21.2.5 NOVARTIS
21.2.6 F. HOFFMANN-LA ROCHE
22 KEY COMPANY PROFILES
22.1 AMGEN
22.1.1 BUSINESS OVERVIEW
22.1.2 PRODUCT OFFERINGS
22.1.3 KEY STRATEGIES
22.1.4 KEY STRENGTHS
22.1.5 KEY OPPORTUNITIES
22.2 BLUEBIRD BIO
22.2.1 BUSINESS OVERVIEW
22.2.2 PRODUCT OFFERINGS
22.2.3 KEY STRATEGIES
22.2.4 KEY STRENGTHS
22.2.5 KEY OPPORTUNITIES
22.3 BRISTOL MYERS SQUIBB
22.3.1 BUSINESS OVERVIEW
22.3.2 PRODUCT OFFERINGS
22.3.3 KEY STRATEGIES
22.3.4 KEY STRENGTHS
22.3.5 KEY OPPORTUNITIES
22.4 GILEAD SCIENCES
22.4.1 BUSINESS OVERVIEW
22.4.2 PRODUCT OFFERINGS
22.4.3 KEY STRATEGIES
22.4.4 KEY STRENGTHS
22.4.5 KEY OPPORTUNITIES
22.5 NOVARTIS
22.5.1 BUSINESS OVERVIEW
22.5.2 PRODUCT OFFERINGS
22.5.3 KEY STRATEGIES
22.5.4 KEY STRENGTHS
22.5.5 KEY OPPORTUNITIES
22.6 F. HOFFMANN-LA ROCHE
22.6.1 BUSINESS OVERVIEW
22.6.2 PRODUCT OFFERINGS
22.6.3 KEY STRATEGIES
22.6.4 KEY STRENGTHS
22.6.5 KEY OPPORTUNITIES
23 GENE THERAPY INVESTIGATIONAL COMPANIES
23.1 4DMT
23.1.1 BUSINESS OVERVIEW
23.2 ABEONA THERAPEUTICS
23.2.1 BUSINESS OVERVIEW
23.3 ANGES
23.3.1 BUSINESS OVERVIEW
23.4 ASKBIO
23.4.1 BUSINESS OVERVIEW
23.5 ASTELLAS GENE THERAPIES
23.5.1 BUSINESS OVERVIEW
23.6 AUTOLUS THERAPEUTICS
23.6.1 BUSINESS OVERVIEW
23.7 CANDEL THERAPEUTICS
23.7.1 BUSINESS OVERVIEW
23.8 CASTLE CREEK BIOSCIENCES
23.8.1 BUSINESS OVERVIEW
23.9 CELLECTIS
23.9.1 BUSINESS OVERVIEW
23.10 EVOX THERAPEUTICS
23.10.1 BUSINESS OVERVIEW
23.11 FREELINE THERAPEUTICS
23.11.1 BUSINESS OVERVIEW
23.12 GENE BIOTHERAPEUTICS
23.12.1 BUSINESS OVERVIEW
23.13 GENERATION BIO
23.13.1 BUSINESS OVERVIEW
23.14 GENSIGHT BIOLOGICS
23.14.1 BUSINESS OVERVIEW
23.15 HELIXMITH
23.15.1 BUSINESS OVERVIEW
23.16 JANSSEN PHARMACEUTICALS
23.16.1 BUSINESS OVERVIEW
23.17 KOLON TISSUE GENE
23.17.1 BUSINESS OVERVIEW
23.18 KRYSTAL BIOTECH
23.18.1 BUSINESS OVERVIEW
23.19 MEIRAGTX
23.19.1 BUSINESS OVERVIEW
23.20 ORCHARD THERAPEUTICS
23.20.1 BUSINESS OVERVIEW
23.21 PFIZER
23.21.1 BUSINESS OVERVIEW
23.22 POSEIDA THERAPEUTICS
23.22.1 BUSINESS OVERVIEW
23.23 PASSAGE BIO
23.23.1 BUSINESS OVERVIEW
23.24 REGENXBIO
23.24.1 BUSINESS OVERVIEW
23.25 SANA BIOTECHNOLOGY
23.25.1 BUSINESS OVERVIEW
23.26 SAREPTA THERAPEUTICS
23.26.1 BUSINESS OVERVIEW
23.27 STRIDEBIO
23.27.1 BUSINESS OVERVIEW
23.28 SOLID BIOSCIENCES
23.28.1 BUSINESS OVERVIEW
23.29 VBL THERAPEUTICS
23.29.1 BUSINESS OVERVIEW
23.30 VOYAGER THERAPEUTICS
23.30.1 BUSINESS OVERVIEW
23.31 UNIQURE
23.31.1 BUSINESS OVERVIEW
24 REPORT SUMMARY
24.1 KEY TAKEAWAYS
24.2 STRATEGIC RECOMMENDATIONS
25 QUANTITATIVE SUMMARY
25.1 MARKET BY VECTOR TYPE
25.2 MARKET BY PRODUCT TYPE
25.3 MARKET BY INDICATION
25.4 MARKET BY GENE TRANSFER
25.5 MARKET BY END-USER
26 APPENDIX
26.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF US GENE THERAPY MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 CLASSIFICATION OF REGENERATIVE MEDICINE
EXHIBIT 4 PAST & PRESENT GENERATIONS OF GENE THERAPY
EXHIBIT 5 PROCESS OF GENE THERAPY
EXHIBIT 6 HISTORY OF GENE THERAPY NIH-FDA OVERSIGHT
EXHIBIT 7 PROCESS OF CLINICAL TRIALS FOR GENE THERAPY PRODUCTS
EXHIBIT 8 FDA-APPROVED COMMERCIALIZED GENE THERAPY PRODUCTS IN THE US
EXHIBIT 9 IMPACT OF INCREASING MARKET ACCESS FOR GENE THERAPIES
EXHIBIT 10 IMPACT OF INTRODUCTION OF UNIVERSAL CAR-T THERAPY
EXHIBIT 11 IMPACT OF INCREASE IN STRATEGIC ACQUISITIONS
EXHIBIT 12 IMPACT OF INCREASED FUNDING FOR R&D ACTIVITIES OF GENE THERAPIES
EXHIBIT 13 IMPACT OF INCREASE IN CMOS TO MANUFACTURE GENE THERAPIES
EXHIBIT 14 MAJOR ADVANTAGES BY ENGAGING WITH CMOS
EXHIBIT 15 FACTORS CONSIDERED ON PARTNERSHIP WITH CONTRACT MANUFACTURERS
EXHIBIT 16 IMPACT OF INCREASING TARGET PATIENT POPULATION
EXHIBIT 17 IMPACT OF PRODUCT LAUNCHES & REGULATORY APPROVALS
EXHIBIT 18 IMPACT OF REGULATORY SUPPORT & SPECIAL DESIGNATIONS FOR GENE THERAPIES
EXHIBIT 19 CUMULATIVE NUMBER OF RMAT REQUESTS RECEIVED BY FDA 2017–2022
EXHIBIT 20 IMPACT OF HIGH COST OF GENE THERAPY PRODUCTS
EXHIBIT 21 IMPACT OF LIMITATIONS OF GENE THERAPY PRODUCTS
EXHIBIT 22 IMPACT OF AVAILABILITY OF ALTERNATIVE THERAPEUTICS & WITHDRAWAL OF PRODUCTS
EXHIBIT 23 US GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 24 US GENE THERAPY MARKET BY VECTOR TYPE: MARKET SHARE 2021 & 2027
EXHIBIT 25 US GENE THERAPY MARKET BY PRODUCT: MARKET SHARE 2021 & 2027
EXHIBIT 26 US GENE THERAPY MARKET BY INDICATION: MARKET SHARE 2021 & 2027
EXHIBIT 27 US GENE THERAPY MARKET BY GENE TRANSFER: MARKET SHARE 2021 & 2027
EXHIBIT 28 US GENE THERAPY MARKET BY END-USERS: MARKET SHARE 2021 & 2027
EXHIBIT 29 FIVE FORCES ANALYSIS 2021
EXHIBIT 30 INCREMENTAL GROWTH BY VECTOR TYPE 2021 & 2027
EXHIBIT 31 US GENE THERAPY MARKET BY VECTOR TYPE
EXHIBIT 32 TYPES OF VECTORS USED IN GENE THERAPY
EXHIBIT 33 US GENE THERAPY MARKET BY VECTOR TYPE: INCREMENTAL GROWTH
EXHIBIT 34 US GENE THERAPY MARKET BY VECTOR TYPE: ABSOLUTE GROWTH
EXHIBIT 35 US RETROVIRAL GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 36 US RETROVIRAL GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 37 NON-VIRAL VECTOR SYSTEMS USED FOR GENE TRANSFER
EXHIBIT 38 US OTHER VECTORS GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 39 US OTHER VECTORS GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 40 INCREMENTAL GROWTH BY PRODUCT TYPE 2021 & 2027
EXHIBIT 41 US GENE THERAPY MARKET BY PRODUCT TYPE
EXHIBIT 42 US GENE THERAPY MARKET BY PRODUCT TYPE: INCREMENTAL GROWTH
EXHIBIT 43 US GENE THERAPY MARKET BY PRODUCT TYPE: ABSOLUTE GROWTH
EXHIBIT 44 US CAR-T GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 45 US CAR-T GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 46 US NON-CAR-T GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 47 US NON-CAR-T GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 48 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 49 US GENE THERAPY MARKET BY INDICATION TYPE
EXHIBIT 50 US GENE THERAPY MARKET BY INDICATION: INCREMENTAL GROWTH
EXHIBIT 51 US GENE THERAPY MARKET BY INDICATION: ABSOLUTE GROWTH
EXHIBIT 52 US ONCOLOGY GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 53 US ONCOLOGY GENE THERAPY MARKET 2021-2027 ($ MILLION)
EXHIBIT 54 US OTHER INDICATIONS GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 55 US OTHER INDICATIONS GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 56 INCREMENTAL GROWTH BY GENE TRANSFER 2021 & 2027
EXHIBIT 57 US GENE THERAPY MARKET BY GENE TRANSFER TYPE
EXHIBIT 58 US GENE THERAPY MARKET BY GENE TRANSFER: INCREMENTAL GROWTH
EXHIBIT 59 US GENE THERAPY MARKET BY GENE TRANSFER: ABSOLUTE GROWTH
EXHIBIT 60 US EX-VIVO GENE THERAPY MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 US EX-VIVO GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 62 US IN-VIVO GENE THERAPY MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 US IN-VIVO GENE THERAPY MARKET 2021–2027 ($ MILLION)
EXHIBIT 64 INCREMENTAL GROWTH BY END-USERS 2021 & 2027
EXHIBIT 65 US GENE THERAPY MARKET BY END-USERS
EXHIBIT 66 US GENE THERAPY MARKET BY END-USERS: INCREMENTAL GROWTH
EXHIBIT 67 US GENE THERAPY MARKET BY END-USERS: ABSOLUTE GROWTH
EXHIBIT 68 US GENE THERAPY MARKET BY HOSPITALS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 US GENE THERAPY MARKET BY HOSPITALS 2021–2027 ($ MILLION)
EXHIBIT 70 US GENE THERAPY MARKET BY CANCER CARE CENTERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 US GENE THERAPY MARKET BY CANCER CARE CENTERS 2021–2027 ($ MILLION)
EXHIBIT 72 US GENE THERAPY MARKET BY ACADEMIC & RESEARCH INSTITUTES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 US GENE THERAPY MARKET BY ACADEMIC & RESEARCH CENTERS 2021–2027 ($ MILLION)
EXHIBIT 74 PURE & DIVERSIFIED VENDORS IN US GENE THERAPY MARKET
EXHIBIT 75 AMGEN: TOTAL REVENUE 2018−2020 ($ MILLION)
EXHIBIT 76 AMGEN: R&D EXPENDITURE 2018−2020 ($ MILLION)
EXHIBIT 77 BLUEBIRD BIO: TOTAL REVENUE 2018−2020 ($ MILLION)
EXHIBIT 78 BLUEBIRD BIO: R&D EXPENDITURE 2018−2020 ($ MILLION)
EXHIBIT 79 BRISTOL MYERS SQUIBB: TOTAL REVENUE 2019−2021 ($ MILLION)
EXHIBIT 80 BRISTOL MYERS SQUIBB: R&D EXPENDITURE 2019−2021 ($ MILLION)
EXHIBIT 81 BRISTOL MYERS SQUIBB: REVENUE BY GEOGRAPHIC REGIONS 2021 ($ MILLION)
EXHIBIT 82 GILEAD SCIENCES: TOTAL REVENUE 2018−2020 ($ MILLION)
EXHIBIT 83 GILEAD SCIENCES: R&D EXPENDITURE 2018−2020 ($ MILLION)
EXHIBIT 84 NOVARTIS: TOTAL REVENUE 2018−2020 ($ MILLION)
EXHIBIT 85 NOVARTIS: R&D EXPENDITURE 2018−2020 ($ MILLION)
EXHIBIT 86 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2019−2020 ($ MILLION)
EXHIBIT 87 NOVARTIS: REVENUE BY GEOGRAPHY 2020 ($ MILLION)
EXHIBIT 88 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2019−2021 ($ BILLION)
EXHIBIT 89 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2019−2021 ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 MAJOR FINANCING CHALLENGES EXIST FOR PAYERS
TABLE 4 EXAMPLES OF GENE THERAPIES LAUNCHED IN US ASSOCIATED WITH HIGH COSTS
TABLE 5 EXEMPLARS OF INNOVATIVE PAYMENT MECHANISMS USED FOR GENE THERAPIES IN US
TABLE 6 GENE THERAPY CLINICAL TRIAL STATUS IN US MARKET
TABLE 7 GENE THERAPY CLINICAL TRIALS IN DIFFERENT PHASES IN US MARKET
TABLE 8 GENE THERAPY CLINICAL TRIALS ENROLLMENT STATUS IN US MARKET
TABLE 9 GENE THERAPY PRODUCTS IN PIPELINE & EXPECTED YEAR OF LAUNCH
TABLE 10 PHARMACEUTICAL COMPANIES & NON-PROFIT ORGANIZATIONS FOR DEVELOPMENT AND UNLOCKING ACCESS TO GENE THERAPIES
TABLE 11 RECENT STRATEGIC ACQUISITIONS IN GENE THERAPY MARKET
TABLE 12 FUNDING OF GENE THERAPY CLINICAL TRIALS LISTED IN 2020
TABLE 13 MAJOR INVESTMENTS BY CMOS IN GENE THERAPY DEVELOPMENT
TABLE 14 TARGET POPULATION & RESPECTIVE GENE THERAPY IN US AS OF 2021
TABLE 15 PRODUCT APPROVALS & LAUNCH DETAILS
TABLE 16 OVERVIEW OF ALL FOUR FDA’S EXPEDITED PROGRAMS
TABLE 17 LIST OF PRODUCTS THAT RECEIVED RMAT DESIGNATION
TABLE 18 COST OF KYMRIAH IN DIFFERENT REGIONS
TABLE 19 FDA APPROVED CAR-T THERAPIES IN THE US
TABLE 20 FDA APPROVED NON-CAR-T THERAPIES IN US
TABLE 21 GENE THERAPY PRODUCTS AVAILABLE FOR CANCER IN US
TABLE 22 GENE THERAPY PRODUCTS AVAILABLE FOR GENETIC DISORDERS IN US
TABLE 23 TOP CANCER CARE CENTERS ACROSS US
TABLE 24 VENDORS OFFERING COMMERCIAL GENE THERAPY PRODUCTS IN US: MARKET DOMINANCE ANALYSIS
TABLE 25 VENDORS OFFERING COMMERCIAL GENE THERAPY PRODUCTS IN US: CAPABILITIES & EXPERTISE ASSESSMENT
TABLE 26 US GENE THERAPY MARKET: VENDOR RANKING
TABLE 27 AMGEN: MAJOR PRODUCT OFFERINGS
TABLE 28 BLUEBIRD BIO: MAJOR PRODUCT OFFERINGS
TABLE 29 BRISTOL MYERS SQUIBB: MAJOR PRODUCT OFFERINGS
TABLE 30 GILEAD SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 31 NOVARTIS: MAJOR PRODUCT OFFERINGS
TABLE 32 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 33 US GENE THERAPY MARKET BY VECTOR TYPE 2021−2027 ($ MILLION)
TABLE 34 US GENE THERAPY MARKET BY VECTOR TYPE 2021−2027 (%)
TABLE 35 US GENE THERAPY MARKET BY PRODUCT TYPE 2021−2027 ($ MILLION)
TABLE 36 US GENE THERAPY MARKET BY PRODUCT TYPE 2021−2027 (%)
TABLE 37 US GENE THERAPY MARKET BY INDICATION 2021−2027 ($ MILLION)
TABLE 38 US GENE THERAPY MARKET BY INDICATION 2021−2027 (%)
TABLE 39 US GENE THERAPY MARKET BY GENE TRANSFER 2021−2027 ($ MILLION)
TABLE 40 US GENE THERAPY MARKET BY GENE TRANSFER 2021−2027 (%)
TABLE 41 US GENE THERAPY MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 42 US GENE THERAPY MARKET BY END-USER 2021−2027 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
